A Covid vaccine compensation scheme could be set up after thousands claimed they have been left disabled as a result of the AstraZeneca jab, The Telegraph has learnt. The Health Secretary is ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Before joining BeiGene, Yin spent 15 years with AstraZeneca, having served in various posts at the British drugmaker, including as head of its oncology business in China. Yin has been detained by ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

NEW YORK – The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on Friday said it would recommend marketing authorization for Novartis' CDK4/6 inhibitor Kisqali ...

(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, ...

FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by patients aged 18-49. FluMist is the first influenza ...

In an interview with China Daily, Sharon Barr, executive vice-president of biopharmaceuticals R&D at AstraZeneca, said the company's presence in Shanghai is absolutely critical to achieving its ...